---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285945797.md"
description: "Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results."
datetime: "2026-05-11T12:40:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285945797.md)
  - [en](https://longbridge.com/en/news/285945797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285945797.md)
---

# 

Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results.

### Related Stocks

- [BCAX.US](https://longbridge.com/en/quote/BCAX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)](https://longbridge.com/en/news/286216781.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data](https://longbridge.com/en/news/286469142.md)